Developing treatments for the diseases that are hardest to treat

 

We wholly own a platform with the potential for treating cancer and selecting patients who would likely benefit from the treatment. Endocyte technology is in mid-stage clinical trials.

PROGRAM INDICATION PHASE PRECLINICAL PHASE 1 PHASE 2 PHASE 3 PARTNERS
Radioligand Therapy (RLT)
177Lu-PSMA-617 mCRPC PHASE 2 (Phase 3 1H 2018) 1H 2018
177Ac-PSMA-617 mCRPC PHASE 1 (Phase 2 4Q 2017) 4Q 2017
225Ac-PSMA-617 mCRPC PRECLINICAL (Phase 1 1H 2018) 1H 2018
CAR T (Adapter Controlled)
Fluorescein CAR T-Cell (FITC CAR T)
FITC CAR T + FITC-Folate CAM Osteosarcoma PRECLINICAL (Phase 1 2H 2018) 2H 2018
FITC CAR T + FITC-CAMs against various targets Solid Tumors PRECLINICAL


Table footnotes
1. CAR: Chimeric Antigen Receptor

* The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.